source
- Create Medicines secures $122M Series B to advance in vivo CAR-T therapiesCreate Medicines, a Cambridge biotech, announced a $122 million Series B financing to expand its in vivo CAR-T cell therapy platform targeting cancer and autoimmune diseases. The round was co-led…
- Biogen advances tau-targeting Alzheimer drug to Phase 3 despite mixed Phase 2 dataBiogen reported results from a Phase 2 trial of its tau-targeting Alzheimer’s candidate diranersen (BIIB080). The study measured tau levels in cerebrospinal fluid and brain tissue of patients with…